Skip to Main Content

Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: Other terms: neuroendocrine NOT Melanoma NOT PMS | Last update posted in the last 30 days
  1. Conditions: Meningioma Interventions: Device: scintigraphy of 177Lu-DOTATATE Sponsors: Central Hospital, Nancy, France Not yet recruiting
  2. Conditions: Neuroendocrine Tumors Interventions: Drug: [18F]-FET-βAG-TOCA Sponsors: Imperial College London; Imperial College Healthcare NHS Trust; Royal Marsden NHS Foundation Trust; University of Manchester; The Christie NHS Foundation Trust; Invicro; Newcastle University Completed
  3. Conditions: Neuroendocrine Tumors Interventions: Drug: 61Cu-NODAGA-LM3; Other: Comparator Sponsors: University Hospital, Basel, Switzerland Not yet recruiting
  4. Conditions: Steatosis of Liver Interventions: Diagnostic Test: Pro-Neurotensin level as a Serum Biomarker Sponsors: Sohag University Not yet recruiting
  5. Conditions: Transgenderism; Reproductive Issues Interventions: Drug: Testosterone Cypionate 50 MG/ML Injectable Solution Sponsors: University of California, San Diego; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Not yet recruiting
  6. Conditions: Gastric Cancer; Gastro Esophageal Junction Cancer Interventions: Drug: Surufatinib; Drug: Sintilimab; Drug: Oxaliplatin; Drug: S1 Sponsors: Fudan University Not yet recruiting
  7. Conditions: Neuroendocrine Tumors Interventions: Diagnostic Test: positron emission tomography (PET) scans Sponsors: Memorial Sloan Kettering Cancer Center; NeuroEndocrine Tumor Research Foundation (NETRF) Recruiting
  8. Conditions: Merkel Cell Carcinoma Interventions: Other: Blood Test Sponsors: University Hospital, Montpellier Not yet recruiting
  9. Conditions: Pheochromocytoma; Paraganglioma Interventions: Procedure: Venepuncture; Procedure: Venepuncture Sponsors: Radboud University Medical Center Not yet recruiting
  10. Conditions: NET; Lymphoma; Solid Tumor, Childhood; Somatostatin Receptor Positive; CNS Tumor Interventions: Drug: Lutetium Lu 177-Edotreotide; Other: Amino Acid Solution Sponsors: ITM Solucin GmbH Not yet recruiting
  11. Conditions: Neuroendocrine Carcinoma Interventions: Biological: ZG006 Sponsors: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Not yet recruiting
  12. Conditions: Pheochromocytoma; Paraganglioma Interventions: Diagnostic Test: FDG-PET Scan Sponsors: King's College Hospital NHS Trust Recruiting
  13. Conditions: Neuroendocrine Tumors; MEN1 Mutation Interventions: Biological: blood sample Sponsors: Centre Hospitalier Universitaire Dijon Recruiting
  14. Conditions: Pheochromocytoma Interventions: Drug: Anlotinib and Penpulimab Sponsors: Sun Yat-sen University; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Recruiting
  15. Conditions: Somatostatin Receptor Positive; Gastrointestinal Neuroendocrine Tumors; Pheochromocytoma; Paragangliomas Interventions: Drug: 68Ga-DOTATATE; Drug: [203Pb]VMT-alpha-NET; Drug: [212Pb]VMT-alpha-NET Sponsors: National Cancer Institute (NCI) Not yet recruiting
  16. Conditions: Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma) Interventions: Drug: FZ-AD005 Sponsors: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Not yet recruiting
  17. Conditions: Thymic Epithelial Tumor; Teratoma; Thymic Cyst; Retrosternal Goitre; Germ Cell Tumor; Lymphoma; Schwannoma Sponsors: Peking Union Medical College Hospital Recruiting
  18. Conditions: Carcinoma, Neuroendocrine; Tumor, Neuroendocrine; Tumors, Neuroendocrine; Neuroendocrine; Carcinoma; Small Cell; Receptors Interventions: Drug: Belinostat; Drug: Cisplatin; Drug: Etoposide Sponsors: National Cancer Institute (NCI) Not yet recruiting
  19. Conditions: Pancreatic Neuroendocrine Tumor Interventions: Diagnostic Test: ATRX/DAXX immunohistochemistry Sponsors: Azienda Ospedaliera Universitaria Integrata Verona Not yet recruiting
  20. Conditions: Metastatic Neuroendocrine Prostate Cancer Interventions: Drug: [68Ga]Ga-PSMA-11; Drug: [68Ga]GA-DOTA-TATE; Drug: [68Ga]Ga-NeoB; Drug: [177Lu]Lu-PSMA-617; Drug: [177Lu]Lu-DOTA-TATE; Drug: [177Lu]Lu-NeoB; Drug: L-Lysine HCl-L-Arginine HCl, 2.5 %,; Drug: Gonadotropin-releasing hormone (GnRH) analogues; Drug: GnRH antagonists; Drug: Antiemetics & antinauseants; Drug: Metoclopramide Sponsors: Novartis Pharmaceuticals Not yet recruiting
  21. Conditions: Neuroendocrine Carcinoma Interventions: Biological: ZG005; Drug: Etoposide; Drug: Cisplatin; Drug: Placebo Sponsors: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting
  22. Conditions: Neuroendocrine Tumors Interventions: Drug: Cessation of somatostatin analogues; Drug: Continuation of somatostatin analogues Sponsors: Australasian Gastro-Intestinal Trials Group; Canadian Cancer Trials Group Not yet recruiting
  23. Conditions: Endocrine Disorders; Adiposity; Pituitary Adenoma; Cushing Syndrome; Acromegaly; Hypopituitarism Sponsors: IRCCS San Raffaele Not yet recruiting
  24. Conditions: Central Nervous System (CNS) Lesions; Brain Metastases; Brain Neoplasms; Brain Neoplasms, Benign; Brain Tumor, Primary; Brain Tumor, Recurrent; Brain Tumors; Brain Cancer; Brain Tumor; Brain Neoplasm, Primary; Multiple Sclerosis; Multiple Sclerosis Brain Lesion; Neurofibroma; Acoustic Neuroma; CNS Tumor; CNS Lesion; CNS Metastases; CNS Cancer; CNS Lymphoma Interventions: Drug: RVP-001 Sponsors: Reveal Pharmaceuticals Inc.; National Cancer Institute (NCI) Recruiting
  25. Conditions: Small Cell Lung Cancer; Neuroendocrine Cancer Interventions: Biological: ZG006 Sponsors: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Not yet recruiting
  26. Conditions: Autoimmune Gastritis Interventions: Other: oral administration of a compound digestive enzyme capsule; Other: oral administration of apple cider vinegar; Other: oral administration of both the compound digestive enzyme capsule and apple cider vinegar Sponsors: Jianning Yao Not yet recruiting
  27. Conditions: Gastro-enteropancreatic Neuroendocrine Tumor; Acromegaly Sponsors: Ipsen Recruiting
  28. Conditions: Depressive Symptoms; Human-Animal Interaction Interventions: Drug: Oxytocin nasal spray; Other: Animal-Assisted Intervention; Drug: Placebo Sponsors: Dr. Karin Hediger Recruiting
  29. Conditions: Small Cell Carcinoma of the Bladder; High Grade Neuroendocrine Tumors of the Urinary Tract Interventions: Drug: Lurbinectedin; Drug: Avelumab Sponsors: National Cancer Institute (NCI) Recruiting
  30. Conditions: Lower Respiratory Tract and Lung Infections; Ventilator Lung; Bronchopneumonia; Bronchitis Interventions: Diagnostic Test: Copeptin level measurement Sponsors: Berker Okay Completed
  31. Conditions: Metastatic Chondrosarcoma; Locally Advanced Chondrosarcoma; Metastatic Sinonasal Adenocarcinoma; Locally Advanced Sinonasal Adenocarcinoma; Metastatic Large-cell Neuroendocrine Carcinoma; Locally Advanced Large-cell Neuroendocrine Carcinoma; Metastatic Olfactory Neuroblastoma; Locally Advanced Olfactory Neuroblastoma; Metastatic Sinonasal Undifferentiated Carcinoma; Locally Advanced Sinonasal Undifferentiated Carcinoma Interventions: Drug: Enasidenib Sponsors: National Cancer Institute (NCI) Recruiting
  32. Conditions: Small Cell Carcinoma of the Bladder; Small Cell Carcinoma of the Urinary Tract; Squamous Cell Carcinoma of the Bladder; Squamous Cell Carcinoma of the Urinary Tract; Primary Adenocarcinoma of the Bladder; Primary Adenocarcinoma of the Urinary Tract; Renal Medullary Carcinoma; Squamous Cell Carcinoma of the Penis Interventions: Drug: Sacituzumab govitecan; Drug: Atezolizumab Sponsors: National Cancer Institute (NCI) Not yet recruiting
  33. Conditions: Advanced Neuroendocrine Carcinoma Interventions: Drug: LBL-024 for Injection; Drug: Etoposide Injection; Drug: Cisplatin for Injection; Drug: Carboplatin Injection Sponsors: Nanjing Leads Biolabs Co.,Ltd Recruiting
  34. Conditions: Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Carboplatin; Drug: Etoposide; Drug: Cisplatin Sponsors: Boehringer Ingelheim Recruiting
  35. Conditions: Neuroendocrine Tumors; Somatostatin Receptor-positive Neuroendocrine Tumor Interventions: Device: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT); Device: Photon Emission Tomography / CT (PET/CT); Drug: 64Cu-Dotatate; Drug: 177Lu-Dotatate Sponsors: University of Wisconsin, Madison Not yet recruiting
  36. Conditions: adrenalDisease Interventions: Procedure: laparoscopic adrenalectomy Sponsors: Zagazig University Completed
  37. Conditions: Idiopathic Intracranial Hypertension Interventions: Procedure: Blood punction; Procedure: Central blood sampling; Procedure: Intracranial pressure measurement Sponsors: University Hospital, Montpellier Recruiting
  38. Conditions: Neuroendocrine Tumors; Colorectal Cancer; Gastric Cancer Interventions: Biological: CHM-2101 CAR-T cells Sponsors: Chimeric Therapeutics Recruiting
  39. Conditions: Neuroendocrine Carcinomas; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Carcinoma, Adrenocortical; Carcinoma, Adrenal Cortical Interventions: Drug: ADCT-701 Sponsors: National Cancer Institute (NCI) Recruiting
  40. Conditions: Sarcoma; Merkel Cell Carcinoma Interventions: Drug: CRD3874 Sponsors: Memorial Sloan Kettering Cancer Center; Curadev Pharma Recruiting
  41. Conditions: Borderline Personality Disorder Interventions: Drug: Hydrocortisone; Dietary Supplement: Yohimbine; Drug: Placebo Sponsors: University of North Carolina, Chapel Hill Withdrawn
  42. Conditions: Advanced Anal Carcinoma; Advanced Biliary Tract Carcinoma; Advanced Bladder Carcinoma; Advanced Breast Carcinoma; Advanced Carcinoid Tumor; Advanced Cervical Carcinoma; Advanced Colorectal Carcinoma; Advanced Gastric Carcinoma; Advanced Glioblastoma; Advanced Head and Neck Carcinoma; Advanced HER2 Positive Breast Carcinoma; Advanced Lung Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Germ Cell Tumor; Advanced Malignant Solid Neoplasm; Advanced Neuroendocrine Carcinoma; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Small Cell Neuroendocrine Carcinoma; Advanced Prostate Carcinoma; Hematopoietic and Lymphoid System Neoplasm; Multiple Myeloma; Myelodysplastic Syndrome Interventions: Procedure: Clinical Encounter; Other: Home Health Encounter; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: Mayo Clinic Recruiting
  43. Conditions: Advanced Solid Tumors Interventions: Drug: INCB099280; Drug: axitinib Sponsors: Incyte Corporation Recruiting
  44. Conditions: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Locally Advanced Merkel Cell Carcinoma; Metastatic Merkel Cell Carcinoma; Refractory Merkel Cell Carcinoma; Unresectable Merkel Cell Carcinoma Interventions: Drug: Avelumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Tuvusertib Sponsors: National Cancer Institute (NCI) Recruiting
  45. Conditions: Small Cell Lung Carcinoma; Neuroendocrine Neoplasms Interventions: Drug: BI 764532, formulation 1; Drug: BI 764532, formulation 2 Sponsors: Boehringer Ingelheim Recruiting
  46. Conditions: Pancreatic Neuroendocrine Tumor Interventions: Diagnostic Test: Blood collection Sponsors: Fudan University Recruiting
  47. Conditions: Somatostatin Receptor-positive Neuroendocrine Tumor Interventions: Other: LUTATHERA Sponsors: Novartis Pharmaceuticals Active, not recruiting
  48. Conditions: Metastatic Midgut Neuroendocrine Tumor; Metastatic Midgut Neuroendocrine Tumor G1; Metastatic Midgut Neuroendocrine Tumor G2; Unresectable Midgut Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI) Recruiting
  49. Conditions: Work Related Stress Interventions: Behavioral: Somatic Psychoeducational Intervention Sponsors: University of Florida Completed
  50. Conditions: Metastatic Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Drug: Triapine Sponsors: National Cancer Institute (NCI) Recruiting